Related Experiment Video

Updated: Apr 11, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

[Molecular biology of castration-resistant prostate cancer]

Ludovic Doucet1, Safae Terrisse1, Hélène Gauthier2

  • 1AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, UFR de médecine, 75890 Paris cedex 18, France.

Bulletin Du Cancer
|June 2, 2015
PubMed

Insights

The androgen receptor (AR) drives prostate cancer even after hormone therapy. New treatments targeting the AR are effective for castration-resistant prostate cancer, highlighting its continued importance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Context:

  • Prostate cancer treatment has evolved, shifting from hormone resistance to focusing on resistance to androgen deprivation therapy (ADT).
  • Recent therapeutic advancements targeting the androgen receptor (AR) demonstrate clinical benefits in patients with progressive disease despite castration.

Purpose:

  • To review the molecular mechanisms underlying castration-resistant prostate cancer (CRPC).
  • To highlight the persistent role of the AR in driving oncogenesis in advanced prostate cancer.

Summary:

  • Castration-resistant prostate cancer (CRPC) is now understood as resistance to androgen deprivation therapy (ADT), not just hormone resistance.
  • The androgen receptor (AR) remains a critical driver of cancer progression in CRPC.
  • New therapies targeting the AR have shown efficacy in patients with progressive CRPC.

Impact:

  • Understanding AR-driven mechanisms in CRPC is crucial for developing more effective treatment strategies.
  • This review provides insights into the molecular basis of CRPC, informing future research and clinical practice.
  • The findings underscore the importance of continued AR-targeted therapies in managing advanced prostate cancer.
Keywords:
Androgen receptorBiologie moléculaireCancer de la prostateCastration resistanceMolecular biologyProstate cancerRécepteur aux androgènesRésistance à la castration

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K